Analyst Ratings For Amedisys
Within the last quarter, Amedisys (NASDAQ:AMED) has observed the following analyst ratings:
Truist Securities Maintains Buy on Amedisys, Lowers Price Target to $190
Truist Securities analyst David Macdonald maintains Amedisys (NASDAQ:AMED) with a Buy and lowers the price target from $255 to $190.
What 9 Analyst Ratings Have To Say About Amedisys
Amedisys (NASDAQ:AMED) has observed the following analyst ratings within the last quarter:
SVB Leerink Initiates Coverage On Amedisys with Market Perform Rating, Announces Price Target of $170
SVB Leerink analyst Whit Mayo initiates coverage on Amedisys (NASDAQ:AMED) with a Market Perform rating and announces Price Target of $170.
Where Amedisys Stands With Analysts
Within the last quarter, Amedisys (NASDAQ:AMED) has observed the following analyst ratings:
UBS Initiates Coverage On Amedisys with Sell Rating, Announces Price Target of $150
UBS initiates coverage on Amedisys (NASDAQ:AMED) with a Sell rating and announces Price Target of $150.
Amedisys To Buy Regulatory Assets Allowing Co. To Establish Home Health Care Centers To Fully Service, Expand Charlotte, Raleigh, North Carolina Markets
Amedisys, Inc. (NASDAQ:AMED), a leading provider of quality home health, hospice and personal care, has signed a definitive agreement to acquire regulatory assets that allow the Company to establish home health care
Where Amedisys Stands With Analysts
Within the last quarter, Amedisys (NASDAQ:AMED) has observed the following analyst ratings: